A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer

Trial Profile

A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms TOHOKU POWER
  • Most Recent Events

    • 18 Oct 2012 Planned End Date 31 Jul 2015 added as reported by University Hospital Medical Information Network - Japan.
    • 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 24 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top